CEL-SCI CORPORATION Ttl Fee Amt
CEL-SCI CORPORATION (CVM) had Ttl Fee Amt of $646.31 as of 2026-08-28, per its S-8 filed 2026-09-03.
Financial Statements › Notes
ffd:TtlFeeAmt · last filed 2026-09-03
- 2026-08-28: Ttl Fee Amt $646.31.
- 2026-04-16: Ttl Fee Amt $2.07K.
| Period end | Ttl Fee Amt |
|---|---|
| 2026-08-28 | $646.31 S-8 · filed 2026-09-03 |
| 2026-04-16 | $2.07K S-1 · filed 2026-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |